Open AccessEvaluation of azacitidine in patients with transplant‑ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia‑related changes in a Japanese clinical setting
Author(s) -
Aya Nakaya,
Shinya Fujita,
Atsushi Satake,
Teruyuki Nakanishi,
Yukio Azuma,
Yukie Tsubokura,
Ryo Saito,
Akiko Konishi,
Masatoshi Hotta,
Hideyuki Yoshimura,
Kazuyoshi Ishii,
Tomoki Ito,
Shosaku Nomura
Publication year - 2019
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2019.11225
Subject(s) - azacitidine , myelodysplastic syndromes , myeloid leukemia , medicine , oncology , myeloid , biology , bone marrow , biochemistry , gene expression , gene , dna methylation
Patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) have exhibited improved overall survival. However, information on AZA in real-world settings is limited. The present study retrospectively analyzed 85 patients with MDS treated with AZA. Complete response was achieved in 24% of cases and hematologic improvement in 29%. Severe adverse events (grade ≥3) included neutropenia and infection. Multivariate analysis identified higher revised international prognostic scoring system (IPSS-R) and male sex as significant factors affecting survival. However, the present study did not identify any significant associations between patient characteristics and response to AZA. In conclusion, AZA could produce a hematologic response in ~53% of patients with MDS. Furthermore, IPSS-R may reflect MDS prognosis. Further studies are required to establish the criteria for identifying patients likely to obtain maximum benefit from AZA treatment.